UTRS (Minerva Surgical) Notes Receivable: $0.00 Mil (As of Sep. 2023)


What is Minerva Surgical Notes Receivable?

Minerva Surgical UTRS -99.00% Notes Receivable is $0.00 Mil as of Sep. 2023.

Minerva Surgical's Notes Receivable for the quarter that ended in Sep. 2023 was $0.00 Mil.

Minerva Surgical Notes Receivable Related Terms

Minerva Surgical Notes Receivable Historical Data

* Premium members only.

The historical data trend for Minerva Surgical's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minerva Surgical Notes Receivable Chart

Minerva Surgical Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Notes Receivable
0.00 0.00 0.00 0.00

Minerva Surgical Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Minerva Surgical Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Minerva Surgical (UTRS) has a Notes Receivable of $0.00 Mil as of Sep. 2023. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Minerva Surgical and its competitors.
Is Minerva Surgical's Notes Receivable too high?
Minerva Surgical's current Notes Receivable is $0.00 Mil.
How does Minerva Surgical's Notes Receivable compare to PAVM and ELUT?
Minerva Surgical's Notes Receivable of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Minerva Surgical and its competitors. Minerva Surgical's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minerva Surgical stock overvalued right now?
Minerva Surgical (UTRS) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Minerva Surgical (UTRS), the current Notes Receivable is $0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minerva Surgical Business Description

Address 4255 Burton Drive, Santa Clara, CA, USA, 95054
Minerva Surgical Inc is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company operates and manages its business as one reportable and operating segment, which is the business of research, development, and sale of therapeutic devices for abnormal uterine bleeding treatment.